Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AIN457 intravenous vs placebo and oral prednisolone on ozone-induced airway neutrophilia in healthy volunteers
2008-002854-39Phase 2Completed
- Sponsor
- Novartis
- Start
- Nov 2008
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of secukinumab (3 arms), sponsored by Novartis. Primary endpoint: Primary: total neutrophil cell count at 24 hours. Started Nov 2008; status: completed.
02
Drugs
secukinumab
Beyond the preview
Go deeper on 2008-002854-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-002854-39.